Tumor Biology

, Volume 37, Issue 2, pp 1567–1571 | Cite as

The study of MED12 gene mutations in uterine leiomyomas from Iranian patients

  • Samaneh Sadeghi
  • Mandana Khorrami
  • Mona Amin-Beidokhti
  • Maryam Abbasi
  • Zeeba Kamalian
  • Shiva Irani
  • Mirdavood Omrani
  • Ozra Azmoodeh
  • Reza Mirfakhraie
Original Article


Uterine leiomyomas are the most common gynecologic benign tumors of the female genital tract that cause a variety of health problems including, abnormal menstrual bleeding, pelvic pain, placenta displacement, premature labor, and miscarriages. Recently, studies showed that recurrent somatic mutations in MED12 exon 2 are the major cause of uterine leiomyomas in different ethnic groups. In order to validate these results in Iranian population, we performed mutational analysis of exon 2 and the flanking intronic regions by using single-strand conformational polymorphism (SSCP) and sequencing analyses in a series of 103 uterine leiomyomas samples. MED12 gene was mutated in 31.07 % of the uterine leiomyomas. Mutations were consisted of 20 missense (62.5 %) and 12 in-frame deletion (37.5 %) mutations and were not detected in normal myometrial tissue. Although this is the lowest mutation frequency reported so far, MED12 mutations are associated with fibroid pathogenesis in the studied population. Understanding the molecular mechanisms responsible for the pathogenesis of uterine leiomyoma will play an important role in designing new therapeutic strategies.


MED12 gene Mutation Uterine leiomyomas 



This study was supported by the Specialized Research Fund from Shahid Beheshti University of Medical Sciences.

Conflicts of interest



  1. 1.
    Feng Y, Lin X, Zhou S, Xu N, Yi T, Zhao X. The associations between the polymorphisms of the ER-alpha gene and the risk of uterine leiomyoma (ULM). Tumour Biol. 2013;34(5):3077–82. doi: 10.1007/s13277-013-0874-0.CrossRefPubMedGoogle Scholar
  2. 2.
    Makinen N, Vahteristo P, Kampjarvi K, Arola J, Butzow R, Aaltonen LA. MED12 exon 2 mutations in histopathological uterine leiomyoma variants. Eur J Hum Genet. 2013;21(11):1300–3. doi: 10.1038/ejhg.2013.33.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bulun SE. Uterine fibroids. N Engl J Med. 2013;369(14):1344–55. doi: 10.1056/NEJMra1209993.CrossRefPubMedGoogle Scholar
  4. 4.
    Makinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334(6053):252–5. doi: 10.1126/science.1208930.CrossRefPubMedGoogle Scholar
  5. 5.
    Makinen N, Heinonen HR, Moore S, Tomlinson IP, van der Spuy ZM, Aaltonen LA. MED12 exon 2 mutations are common in uterine leiomyomas from South African patients. Oncotarget. 2011;2(12):966–9.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Turunen M, Spaeth JM, Keskitalo S, Park MJ, Kivioja T, Clark AD, et al. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity. Cell Rep. 2014;7(3):654–60. doi: 10.1016/j.celrep.2014.03.047.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Galbraith MD, Donner AJ, Espinosa JM. CDK8: a positive regulator of transcription. Transcription. 2010;1(1):4–12. doi: 10.4161/trns.1.1.12373.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kim S, Xu X, Hecht A, Boyer TG. Mediator is a transducer of Wnt/beta-catenin signaling. J Biol Chem. 2006;281(20):14066–75. doi: 10.1074/jbc.M602696200.CrossRefPubMedGoogle Scholar
  9. 9.
    Markowski DN, Bartnitzke S, Loning T, Drieschner N, Helmke BM, Bullerdiek J. MED12 mutations in uterine fibroids—their relationship to cytogenetic subgroups. Int J Cancer. 2012;131(7):1528–36. doi: 10.1002/ijc.27424.CrossRefPubMedGoogle Scholar
  10. 10.
    Heinonen HR, Sarvilinna NS, Sjoberg J, Kampjarvi K, Pitkanen E, Vahteristo P, et al. MED12 mutation frequency in unselected sporadic uterine leiomyomas. Fertil Steril. 2014;102(4):1137–42. doi: 10.1016/j.fertnstert.2014.06.040.CrossRefPubMedGoogle Scholar
  11. 11.
    Halder SK, Laknaur A, Miller J, Layman LC, Diamond M, Al-Hendy A. Novel MED12 gene somatic mutations in women from the southern United States with symptomatic uterine fibroids. Mol Genet Genomics. 2015;290(2):505–11. doi: 10.1007/s00438-014-0938-x.CrossRefPubMedGoogle Scholar
  12. 12.
    Templeman C, Marshall SF, Clarke CA, Henderson KD, Largent J, Neuhausen S, et al. Risk factors for surgically removed fibroids in a large cohort of teachers. Fertil Steril. 2009;92(4):1436–46. doi: 10.1016/j.fertnstert.2008.08.074.CrossRefPubMedGoogle Scholar
  13. 13.
    Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams-Campbell LL, et al. Risk of uterine leiomyomata in relation to tobacco, alcohol and caffeine consumption in the Black Women’s Health Study. Hum Reprod. 2004;19(8):1746–54. doi: 10.1093/humrep/deh309.CrossRefPubMedGoogle Scholar
  14. 14.
    Liechti-Gallati S, Schneider V, Neeser D, Kraemer R. Two buffer PAGE system-based SSCP/HD analysis: a general protocol for rapid and sensitive mutation screening in cystic fibrosis and any other human genetic disease. Eur J Hum Genet. 1999;7(5):590–8. doi: 10.1038/sj.ejhg.5200338.CrossRefPubMedGoogle Scholar
  15. 15.
    Laughlin SK, Baird DD, Savitz DA, Herring AH, Hartmann KE. Prevalence of uterine leiomyomas in the first trimester of pregnancy: an ultrasound-screening study. Obstet Gynecol. 2009;113(3):630–5. doi: 10.1097/AOG.0b013e318197bbaf.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Bertsch E, Qiang W, Zhang Q, Espona-Fiedler M, Druschitz S, Liu Y, et al. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Mod Pathol. 2014;27(8):1144–53. doi: 10.1038/modpathol.2013.243.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Je EM, Kim MR, Min KO, Yoo NJ, Lee SH. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors. Int J Cancer. 2012;131(6):E1044–7. doi: 10.1002/ijc.27610.CrossRefPubMedGoogle Scholar
  18. 18.
    McGuire MM, Yatsenko A, Hoffner L, Jones M, Surti U, Rajkovic A. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PLoS One. 2012;7(3), e33251. doi: 10.1371/journal.pone.0033251.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Di Tommaso S, Tinelli A, Malvasi A, Massari S. Missense mutations in exon 2 of the MED12 gene are involved in IGF-2 overexpression in uterine leiomyoma. Mol Hum Reprod. 2014;20(10):1009–15. doi: 10.1093/molehr/gau055.CrossRefPubMedGoogle Scholar
  20. 20.
    Kampjarvi K, Park MJ, Mehine M, Kim NH, Clark AD, Butzow R, et al. Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas. Hum Mutat. 2014;35(9):1136–41. doi: 10.1002/humu.22612.CrossRefPubMedGoogle Scholar
  21. 21.
    Guo X, Wang XF. A mediator lost in the war on cancer. Cell. 2012;151(5):927–9. doi: 10.1016/j.cell.2012.11.003S0092-8674(12)01344-X.CrossRefPubMedGoogle Scholar
  22. 22.
    Markowski DN, Nimzyk R, Belge G, Loning T, Helmke BM, Bullerdiek J. Molecular topography of the MED12-deleted region in smooth muscle tumors: a possible link between non-B DNA structures and hypermutability. Mol Cytogenet. 2013;6(1):23. doi: 10.1186/1755-8166-6-23.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Zhang P, Zhang C, Hao J, Sung CJ, Quddus MR, Steinhoff MM, et al. Use of X-chromosome inactivation pattern to determine the clonal origins of uterine leiomyoma and leiomyosarcoma. Hum Pathol. 2006;37(10):1350–6. doi: 10.1016/j.humpath.2006.05.005.CrossRefPubMedGoogle Scholar
  24. 24.
    Nataraj AJ, Olivos-Glander I, Kusukawa N, Highsmith Jr WE. Single-strand conformation polymorphism and heteroduplex analysis for gel-based mutation detection. Electrophoresis. 1999;20(6):1177–85. doi: 10.1002/(SICI)1522-2683(19990101)20:6<1177::AID-ELPS1177>3.0.CO;2-2.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Samaneh Sadeghi
    • 1
  • Mandana Khorrami
    • 2
  • Mona Amin-Beidokhti
    • 1
  • Maryam Abbasi
    • 2
  • Zeeba Kamalian
    • 1
  • Shiva Irani
    • 2
  • Mirdavood Omrani
    • 1
  • Ozra Azmoodeh
    • 3
  • Reza Mirfakhraie
    • 1
    • 4
  1. 1.Department of Medical Genetics, School of MedicineShahid Beheshti University of Medical SciencesTerhanIran
  2. 2.Department of BiologyIslamic Azad University of Tehran, Science and Research BranchTehranIran
  3. 3.Mirza Koochak Khan HospitalTehran University of Medical SciencesTehranIran
  4. 4.Genomic Research CenterShahid Beheshti University of Medical SciencesTehranIran

Personalised recommendations